ARDELYX, INC. 10-Q

ITEM 5. OTHER INFORMATION Trading Plans During the three months ended June 30, 2025, certain of our Section 16 officers and directors adopted or terminated contracts, instructions or written plans for the purchase or sale of our securities as noted below. Name and Title of Director or Officer Action Date Trading Arrangement Total Shares Available to be Sold Expiration Date Rule 10b5-1* Non-Rule 10b5-1** Laura Williams , Chief Patient Officer Adoption May 27, 2025 X 130,000 May 1, 2026 * Intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) ** Not intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) 60 Table of Contents ITEM 6. EXHIBITS Exhibit Number Incorporated by Reference Filed Herewith Exhibit Description Form Date Number 3.1 Amended and Restated Certificate of Incorporation. 8-K 06/24/2024 3.1 3.2 Certificate of Amendment to Amended and Restated Certificate of Incorporation. 8-K 06/20/2023 3.1 3.3 Second Amended and Restated Bylaws. 8-K 08/04/2025 3.1 10.1# First Amendment to the Ardelyx, Inc. Amended and Restated 2014 Equity Plan Amendment. 8-K 06/18/2025 10.1 10.2 Amendment Number 4 to Lease Agreement by and between Ardelyx, Inc, and Prospect Fifth Avenue, LLC. X 10.3# Offer Letter, dated April 10, 2025 by and between Ardelyx, Inc. and James P. Brady. X 10.4 Fifth Amendment to Loan and Security Agreement, dated June 30, 2025, by and among the Company, SLR Investment Corp., as collateral agent, and the lenders party thereto . 8-K 07/03/2025 10.1 31.1 Certification of Chief Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. X 31.2 Certification of Chief Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. X 32.1* Certification of Chief Executive Officer and Chief Financial Officer Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. X 101 The following financial statements, formatted in Inline Extensible Business Reporting Language (XBRL): (i) Condensed Balance Sheets as of June 30, 2025 and December 31, 2024, (ii) Condensed Statements of Operations and Comprehensive Loss for the three and six months ended June 30, 2025 and 2024, (iii) Condensed Statements of Changes in Stockholders’ Equity for the three and six months ended June 30, 2025 and 2024, (iv) Condensed Statements of Cash Flows for the six months ended June 30, 2025 and 2024, and (v) Notes to Unaudited Condensed Financial Statements. X 104 Cover Page Interactive Data File, formatted in Inline XBRL and contained in Exhibit 101. X _______________________________ # Indicates management contract or compensatory plan. *The certification attached as Exhibit 32.1 that accompanies this Quarterly Report on Form 10-Q, is deemed furnished and not filed with the SEC and is not to be incorporated by reference into any filing of Ardelyx, Inc. under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date of this Quarterly Report on Form 10-Q, irrespective of any general incorporation language contained in such filing. 61 Table of Contents SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Ardelyx, Inc. Date: August 4, 2025 By: /s/ Joseph Reilly Joseph Reilly Senior Vice President and Chief Accounting Officer (Principal Accounting Officer) 62 Table of Contents SUMMARY OF ABBREVIATED TERMS Throughout this Quarterly Report on Form 10-Q, we have used terms which are defined below: 340B Program Public Health Service’s 340B Drug Pricing Program GTN gross-to-net AAKP American Association of Kidney Patients HCR HealthCare Royalty Partners IV, L.P. ACA Affordable Care Act HCR Agreement Royalty and Sales Milestone Interest Acquisition Agreement AI Technologies Artificial intelligence, machine learning and certain automated decision-making technologies HHS Department of Health and Human Services AMP average manufacturer price HIPAA Health Insurance Portability and Accountability Act of 1996, as amended, and regulations promulgated thereunder ANDA abbreviated New Drug Application HRSA Health Resources and Services Administration 2024 Form 10-K Annual Report on Form 10-K for the year ended December 31, 2024 filed with the SEC on February 20, 2025 IBS-C irritable bowel syndrome with constipation API active pharmaceutical ingredient IND Investigational New Drug AstraZeneca AstraZeneca AB IRA Inflation Reduction Act of 2022 ASU Accounting Standards Update IRB institutional review board CCPA California Consumer Privacy Act, as amended by the California Privacy Rights Act Jefferies Jefferies, LLC cGMP current Good Manufacturing Practice Kyowa Kirin Kyowa Kirin Co., Ltd. CKD chronic kidney disease Knight Knight Therapeutics, Inc. CME Chicago Mercantile Exchange MDRP Medicaid Drug Rebate Program CMO contract manufacturing organization METiS METiS Therapeutics, Inc. CMS Centers for Medicare & Medicaid Services MHLW Ministry of Health, Labour and Welfare CRO contract research organization MIPPA Medicare Improvements for Patients and Providers Act CODM Chief Operating Decision Maker OLC Oxylanthanum Carbonate Customers collectively, major wholesalers, specialty pharmacies and GPOs (IBSRELA) and specialty wholesaler (XPHOZAH) NCE new chemical entity DPF EU-US Data Privacy Framework NDA New Drug Application EEA European Economic Area NH3 sodium hydrogen exchange 3 ESPP Employee Stock Purchase Plan NMPA National Medical Products Administration ESRD End-Stage Renal Disease NOL net operating loss ESRD PPS End-Stage Renal Disease Prospective Payment System NMQF National Minority Quality Forum EU Patent Package European Patent Package Non-FAMP Non-Federal Average Manufacturer Price Exchange Act the Securities Exchange Act of 1934, as amended R&D research and development FASB Financial Accounting Standards Board REMS Risk Evaluation and Mitigation Strategy FDA Food and Drug Administration RSU restricted stock units FFDCA Federal Food, Drug, and Cosmetic Act SLR SLR Investment Corp. Fosun Pharma Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. SEC Securities and Exchange Commission FSS Federal Supply Schedule SOFR Secured Overnight Financing Rate FTC Federal Trade Commission TDAPA Transitional Drug Add-on Payment Adjustment GAAP generally accepted accounting principles UPC European Unified Patent Court GCP Good Clinical Practice U.S. United States GDPR European Union General Data Protection Regulation USPTO U.S. Patent and Trademark Office GLP Good Laboratory Practice VA Department of Veterans Affairs GPO group purchasing organization 63